[Novel therapeutic agents for myelodysplastic syndrome].
Ishikawa
Takayuki
T
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D000077209:Decitabine; D055808:Drug Discovery; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage; D006801:Humans; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D004921:Erythropoietin; D013792:Thalidomide; D000077209:Decitabine; D000077269:Lenalidomide; D001374:Azacitidine